Richard Aldrich - Net Worth and Insider Trading

Richard Aldrich Net Worth

The estimated net worth of Richard Aldrich is at least $15 Million dollars as of 2024-09-20. Richard Aldrich is the Director of KalVista Pharmaceuticals Inc and owns about 934,484 shares of KalVista Pharmaceuticals Inc (KALV) stock worth over $10 Million. Richard Aldrich is the Director of Concert Pharmaceuticals Inc and owns about 596,977 shares of Concert Pharmaceuticals Inc (CNCE) stock worth over $5 Million. Richard Aldrich is also the Director of Verastem Inc and owns about 58,953 shares of Verastem Inc (VSTM) stock worth over $166,837. Besides these, Richard Aldrich also holds Millendo Therapeutics Inc (MLND) , PTC Therapeutics Inc (PTCT) . Details can be seen in Richard Aldrich's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Richard Aldrich has not made any transactions after 2022-06-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Richard Aldrich

Richard Aldrich Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Richard Aldrich owns 11 companies in total, including Concert Pharmaceuticals Inc (CNCE) , Millendo Therapeutics Inc (MLND) , and KalVista Pharmaceuticals Inc (KALV) among others .

Click here to see the complete history of Richard Aldrich’s form 4 insider trades.

Insider Ownership Summary of Richard Aldrich

Ticker	Comapny	Transaction Date	Type of Owner
CNCE	Concert Pharmaceuticals Inc	2022-06-06	director
MLND	Millendo Therapeutics Inc	2018-12-07	director
KALV	KalVista Pharmaceuticals Inc	2017-10-12	director
		2015-06-08	director
		2014-05-20	director
		2008-11-17	10 percent owner
		2008-10-29	10 percent owner
		2008-07-10	10 percent owner
		2007-08-08	10 percent owner
		2006-09-28	director
		2013-06-07	director & 10 percent owner

Richard Aldrich Latest Holdings Summary

Richard Aldrich currently owns a total of 5 stocks. Among these stocks, Richard Aldrich owns 934,484 shares of KalVista Pharmaceuticals Inc (KALV) as of October 12, 2017, with a value of $10 Million and a weighting of 66.52%. Richard Aldrich owns 596,977 shares of Concert Pharmaceuticals Inc (CNCE) as of June 6, 2022, with a value of $5 Million and a weighting of 32.34%. Richard Aldrich also owns 58,953 shares of Verastem Inc (VSTM) as of May 20, 2014, with a value of $166,837 and a weighting of 1.08%. The other 2 stocks Millendo Therapeutics Inc (MLND) , PTC Therapeutics Inc (PTCT) have a combined weighting of 0.06% among all his current holdings.

Latest Holdings of Richard Aldrich

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
KALV	KalVista Pharmaceuticals Inc	2017-10-12	934,484	11.00	10,279,324
CNCE	Concert Pharmaceuticals Inc	2022-06-06	596,977	8.37	4,996,697
VSTM	Verastem Inc	2014-05-20	58,953	2.83	166,837
MLND	Millendo Therapeutics Inc	2016-06-01	8,729	1.06	9,253
PTCT	PTC Therapeutics Inc	2015-06-08	0	36.16	0

Holding Weightings of Richard Aldrich

Richard Aldrich Form 4 Trading Tracker

According to the SEC Form 4 filings, Richard Aldrich has made a total of 0 transactions in KalVista Pharmaceuticals Inc (KALV) over the past 5 years. The most-recent trade in KalVista Pharmaceuticals Inc is the acquisition of 565,065 shares on October 12, 2017, which cost Richard Aldrich around $5 Million.

According to the SEC Form 4 filings, Richard Aldrich has made a total of 1 transactions in Concert Pharmaceuticals Inc (CNCE) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Concert Pharmaceuticals Inc is the acquisition of 210,526 shares on June 6, 2022, which cost Richard Aldrich around $999,998.

According to the SEC Form 4 filings, Richard Aldrich has made a total of 0 transactions in Verastem Inc (VSTM) over the past 5 years. The most-recent trade in Verastem Inc is the acquisition of 83 shares on May 20, 2014, which cost Richard Aldrich around $8,370.

More details on Richard Aldrich's insider transactions can be found in the Insider Trading History of Richard Aldrich table.

Insider Trading History of Richard Aldrich

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Richard Aldrich Trading Performance

GuruFocus tracks the stock performance after each of Richard Aldrich's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Richard Aldrich is 6.58%. GuruFocus also compares Richard Aldrich's trading performance to market benchmark return within the same time period. The performance of stocks bought by Richard Aldrich within 3 months outperforms 20 times out of 48 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Richard Aldrich's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Richard Aldrich

Average Return

Average return per transaction

Outperforming Transactions

14 out of 47 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-0.46
Relative Return to S&P 500(%)	-1.75

Richard Aldrich Ownership Network

Ownership Network List of Richard Aldrich

No Data

Ownership Network Relation of Richard Aldrich

Richard Aldrich Owned Company Details

What does Concert Pharmaceuticals Inc do?

Who are the key executives at Concert Pharmaceuticals Inc?

Richard Aldrich is the director of Concert Pharmaceuticals Inc. Other key executives at Concert Pharmaceuticals Inc include Chief Development Officer James V Cassella , CFO & PFO Marc A. Becker , and Chief Operating Officer Nancy Stuart .

Concert Pharmaceuticals Inc (CNCE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Concert Pharmaceuticals Inc (CNCE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Concert Pharmaceuticals Inc (CNCE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Concert Pharmaceuticals Inc (CNCE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Concert Pharmaceuticals Inc Insider Transactions

No Available Data

What does Millendo Therapeutics Inc do?

Who are the key executives at Millendo Therapeutics Inc?

Richard Aldrich is the director of Millendo Therapeutics Inc. Other key executives at Millendo Therapeutics Inc include General Counsel and Secretary Tamara L Joseph , Chief Financial Officer Arcudi Iii Louis J , and director & President and CEO Julia C. Owens .

Millendo Therapeutics Inc (MLND) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Millendo Therapeutics Inc (MLND) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Millendo Therapeutics Inc (MLND) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Millendo Therapeutics Inc (MLND)'s detailed insider trading history can be found in Insider Trading Tracker table.

Millendo Therapeutics Inc Insider Transactions

No Available Data

What does KalVista Pharmaceuticals Inc do?

Who are the key executives at KalVista Pharmaceuticals Inc?

Richard Aldrich is the director of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include CFO and Secretary Benjamin L Palleiko , Chief Medical Officer Paul K. Audhya , and Chief Development Officer Christopher Yea .

KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary

Over the past 18 months, Richard Aldrich made no insider transaction in KalVista Pharmaceuticals Inc (KALV). Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net purchase of 1,251,017 shares made by Venrock Healthcare Capital Partners Iii, L.p. , a net sale of 144,760 shares made by Benjamin L Palleiko , and a net sale of 116,267 shares made by Edward P. Feener .

In summary, during the past 3 months, insiders sold 40,693 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 40,693 shares. During the past 18 months, 583,370 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 1,251,017 shares were bought by its insiders, resulting in a net purchase of 667,647 shares.

KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.

KalVista Pharmaceuticals Inc Insider Transactions

No Available Data

What does PTC Therapeutics Inc do?

Who are the key executives at PTC Therapeutics Inc?

Richard Aldrich is the director of PTC Therapeutics Inc. Other key executives at PTC Therapeutics Inc include CHIEF FINANCIAL OFFICER Pierre Gravier , Chief Medical Officer Lee Scott Golden , and Chief Development Officer Matthew B. Klein .

PTC Therapeutics Inc (PTCT) Insider Trades Summary

Over the past 18 months, Richard Aldrich made no insider transaction in PTC Therapeutics Inc (PTCT). Other recent insider transactions involving PTC Therapeutics Inc (PTCT) include a net sale of 22,771 shares made by Eric Pauwels , a net sale of 39,197 shares made by Christine Marie Utter , and a net sale of 23,666 shares made by Matthew B. Klein .

In summary, during the past 3 months, insiders sold 2,269 shares of PTC Therapeutics Inc (PTCT) in total and bought 0 shares, with a net sale of 2,269 shares. During the past 18 months, 270,326 shares of PTC Therapeutics Inc (PTCT) were sold and 7,700 shares were bought by its insiders, resulting in a net sale of 262,626 shares.

PTC Therapeutics Inc (PTCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

PTC Therapeutics Inc Insider Transactions

No Available Data

What does Verastem Inc do?

Who are the key executives at Verastem Inc?

Richard Aldrich is the director of Verastem Inc. Other key executives at Verastem Inc include Chief Operating Officer Dan Paterson , Chief Financial Officer Robert E. Gagnon , and Vice President of Finance Daniel Calkins .

Verastem Inc (VSTM) Insider Trades Summary

Over the past 18 months, Richard Aldrich made no insider transaction in Verastem Inc (VSTM). Other recent insider transactions involving Verastem Inc (VSTM) include a net sale of 1,022 shares made by Daniel Calkins , a net sale of 20,757 shares made by Robert E. Gagnon , and a net sale of 5,621 shares made by Dan Paterson .

In summary, during the past 3 months, insiders sold 4,413 shares of Verastem Inc (VSTM) in total and bought 0 shares, with a net sale of 4,413 shares. During the past 18 months, 31,598 shares of Verastem Inc (VSTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 31,598 shares.

Verastem Inc (VSTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verastem Inc Insider Transactions

No Available Data

What does BioSpecifics Technologies Corp do?

Who are the key executives at BioSpecifics Technologies Corp?

Richard Aldrich is the 10 percent owner of BioSpecifics Technologies Corp. Other key executives at BioSpecifics Technologies Corp include director & 10 percent owner Toby Wegman , director & Chief Executive Officer Joseph Truitt , and Chief Financial Officer Patrick Hutchison .

BioSpecifics Technologies Corp (BSTC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of BioSpecifics Technologies Corp (BSTC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of BioSpecifics Technologies Corp (BSTC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

BioSpecifics Technologies Corp (BSTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

BioSpecifics Technologies Corp Insider Transactions

No Available Data

What does Aradigm Corp do?

Who are the key executives at Aradigm Corp?

Richard Aldrich is the 10 percent owner of Aradigm Corp. Other key executives at Aradigm Corp include 10 percent owner Bleichroeder Lp , 10 percent owner First Eagle Investment Management, Llc , and 10 percent owner First Eagle Value In Biotechnology Master Fund, Ltd. .

Aradigm Corp (ARDMQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aradigm Corp (ARDMQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aradigm Corp (ARDMQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aradigm Corp (ARDMQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aradigm Corp Insider Transactions

No Available Data

What does Sequenom Inc do?

Who are the key executives at Sequenom Inc?

Richard Aldrich is the 10 percent owner of Sequenom Inc. Other key executives at Sequenom Inc include director & EVP and Treasurer Glenn A Eisenberg , director & Chairman & President & Sec Eberts F Samuel Iii , and Sr VP & GC & Secretary Jeffrey D Linton .

Sequenom Inc (SQNM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sequenom Inc (SQNM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sequenom Inc (SQNM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sequenom Inc (SQNM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sequenom Inc Insider Transactions

No Available Data

What does Curis Inc do?

Who are the key executives at Curis Inc?

Richard Aldrich is the 10 percent owner of Curis Inc. Other key executives at Curis Inc include CDO Jonathan B. Zung , CFO Diantha Duvall , and Head of Research & Development Robert Martell .

Curis Inc (CRIS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Curis Inc (CRIS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Curis Inc (CRIS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Curis Inc (CRIS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Curis Inc Insider Transactions

No Available Data

What does EPIRUS Biopharmaceuticals Inc do?

Who are the key executives at EPIRUS Biopharmaceuticals Inc?

Richard Aldrich is the director of EPIRUS Biopharmaceuticals Inc. Other key executives at EPIRUS Biopharmaceuticals Inc include Chief Business Officer Vincent Aurentz , Chief Financial Officer Thomas A. Shea , and director & Chief Executive Officer Amit Munshi .

EPIRUS Biopharmaceuticals Inc (EPRSQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

EPIRUS Biopharmaceuticals Inc (EPRSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

EPIRUS Biopharmaceuticals Inc Insider Transactions

No Available Data

What does Tempest Therapeutics Inc do?

Who are the key executives at Tempest Therapeutics Inc?

Richard Aldrich is the director & 10 percent owner of Tempest Therapeutics Inc. Other key executives at Tempest Therapeutics Inc include 10 percent owner Versant Venture Capital Vi, L.p. , director & Chief Executive Officer Stephen R Brady , and Chief Medical Officer Samuel Whiting .

Tempest Therapeutics Inc (TPST) Insider Trades Summary

Over the past 18 months, Richard Aldrich made no insider transaction in Tempest Therapeutics Inc (TPST). Other recent insider transactions involving Tempest Therapeutics Inc (TPST) include a net sale of 787,999 shares made by Versant Venture Capital Vi, L.p. , a net purchase of 35,000 shares made by Stephen R Brady , and a net purchase of 4,672 shares made by Samuel Whiting .

In summary, during the past 3 months, insiders sold 787,999 shares of Tempest Therapeutics Inc (TPST) in total and bought 39,672 shares, with a net sale of 748,327 shares. During the past 18 months, 787,999 shares of Tempest Therapeutics Inc (TPST) were sold and 39,672 shares were bought by its insiders, resulting in a net sale of 748,327 shares.

Tempest Therapeutics Inc (TPST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tempest Therapeutics Inc Insider Transactions

No Available Data

Richard Aldrich Mailing Address

Above is the net worth, insider trading, and ownership report for Richard Aldrich. You might contact Richard Aldrich via mailing address: 1365 Main Street, Waltham Ma 02451.

Discussions on Richard Aldrich

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.